Document is current
Any future updates will be listed below
-
Authors
Poder, Thomas G.
Harris, Philippe
Têtu, Maxime
Mondoloni, Pascal
Vernelus, Cathy
Mignault, Alexandre
Liberman, Moishe
-
Funding
Funding for this research was provided by:
Fonds de soutien à l’innovation en santé et services sociaux
Marcel and Rolande Gosselin Chair in Thoracic Surgical Oncology
- License Information
-
More Information
Article History
Received: 19 December 2024
Accepted: 5 February 2025
First Online: 17 February 2025
Declarations
:
: The study was approved by the Institutional Review Board (IRB) of the Research Center of the Centre Hospitalier de l’Université de Montréal (CRCHUM) under approval CRCHUM IRB#: 21.009 in May 2021. All patient data were anonymized.
: For this retrospective cost-analysis study, the IRB waived the requirement for informed consent.
: Not commissioned, externally peer-reviewed.
: Thomas G Poder: received payment from AssistIQ to perform economic analysis and acted independently; Moishe Liberman: Chief Medical Officer at AssistIQ; Maxime Têtu: clinical product specialist at AssistIQ; other authors: none declared.
